Effects of chitosan on plasma lipids and lipoproteins: A 4-month prospective pilot study

Angiology

Volumn 65, Issue 6, 2014, Pages 538-542

  Rizzo, Manfredi ^a,b,c   Giglio, Rosaria Vincenza ^a   Nikolic, Dragana ^a   Patti, Angelo Maria ^a   Campanella, Claudia ^a,b   Cocchi, Massimo ^c   Katsiki, Niki ^d   Montalto, Giuseppe ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Euro Mediterranean Institute of Science and Technology   (Italy)

^c Department of Veterinary Medical Sciences   (Switzerland)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

chitosan; lipids; lipoproteins; therapy

Indexed keywords

CHITOSAN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; MALE; MIDDLE AGED; PILOT STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; BLOOD; BODY MASS; PROSPECTIVE STUDY; WAIST CIRCUMFERENCE;

ANTICHOLESTEREMIC AGENTS; BODY MASS INDEX; CHITOSAN; CHOLESTEROL; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 84903513597     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319713493126     Document Type: Article

References (39)

1. Ormrod DJ, Holmes CC, Miller TE. Dietary chitosan inhibits hypercholesterolaemia and atherogenesis in the apolipoprotein E-deficient mouse model of atherosclerosis. Atherosclerosis. 1998 ; 138 (2). 329-334
2. Nauss JL, Thompson JL, Nagyuvary J. The binding of micellar lipids to chitosan. Lipids. 1983 ; 18 (10). 714-719
3. Ernst E, Pittler MH. A metaanalysis of chitosan for body weight reduction. Perfusion. 1998 ; 11 (11). 461-465
4. Majeti NV, Ravi Kumar MNV. A review of chitin and chitosan applications. React Funct Polym. 2000 ; 46 (1). 1-27
5. Gallaher DD, Gallaher CM, Mahrt GJ, et al. A glucomannan and chitosan fiber supplement decreases plasma cholesterol and increases cholesterol excretion in overweight normocholesterolemic humans. J Am Coll Nutr. 2002 ; 21 (5). 428-433
6. Ray SD. Potential aspects of chitosan as pharmaceutical excipient. Acta Pol Pharm. 2011 ; 68 (5). 619-622
7. Ausar SF, Morcillo M, León AE, et al. Improvement of HDL- and LDL-cholesterol levels in diabetic subjects by feeding bread containing chitosan. J Med Food. 2003 ; 6 (4). 397-399
8. Tai TS, Sheu WH, Lee WJ, Yao HT, Chiang MT. Effect of chitosan on plasma lipoprotein concentrations in type 2 diabetic subjects with hypercholesterolemia. Diabetes Care. 2000 ; 23 (11). 1703-1704
9. Baker WL, Tercius A, Anglade M, White CM, Coleman CI. A meta-analysis evaluating the impact of chitosan on serum lipids in hypercholesterolemic patients. Ann Nutr Metab. 2009 ; 55 (4). 368-374
10. Wang D, Han J, Yu Y, et al. Chitosan oligosaccharide decreases very-low-density lipoprotein triglyceride and increases high-density lipoprotein cholesterol in high-fat-diet-fed rats. Exp Biol Med (Maywood). 2011 ; 236 (9). 1064-1069
11. Rizzo M, Mikhailidis DP. There is more to predicting vascular disease than just established risk factors. Curr Pharm Des. 2011 ; 17 (33). 3608-3610
12. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005 ; 112 (17). 2735-2752
13. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974 ; 20 (4). 470-475
14. Nägele U, Hägele EO, Sauer G, et al. Reagent for the enzymatic determination of serum total triglycerides with improved lipolytic efficiency. J Clin Chem Clin Biochem. 1984 ; 22 (2). 165-174
15. Warnick GR, Nguyen T, Albers JJ. Comparison of improved precipitation methods for quantification of high density lipoprotein cholesterol. Clin Chem. 1985 ; 31 (2). 217-222
16. Hoefner DM, Hodel SD, O'Brien JF, et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem. 2001 ; 47 (2). 266-274
17. Mikhailidis DP, Elisaf MS. Rizzo M, et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011 ; 9 (5). 533-571
18. Kalogirou M, Tsimihodimos V, Gazi I, et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin. 2007 ; 23 (5). 1169-1176
19. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 ; 106 (25). 3143-3421
20. Mikhailidis DP, Elisaf MS. Rizzo M, et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol. 2011 ; 9 (5). 531-532
21. Rizzo M, Berneis K. Should we measure routinely the LDL peak particle size?. Int J Cardiol. 2006 ; 107 (2). 147-151
22. Bjornheden T, Babyi A, Bondjers G, Wiklund O. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis. 1996 ; 123 (1-2). 43-56
23. Camejo G, Lopez A, Lopez F, Quinones J.. Interaction of low density lipoproteins with arterial proteoglycans. The role of charge and sialic acid content. Atherosclerosis. 1985 ; 55 (1). 93-105
24. Tribble DL, Rizzo M, Chait A, Lewis DM, Blanche PJ, Krauss RM. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. Am J Med. 2001 ; 110 (2). 103-110
25. Egras AM, Hamilton WR, Lenz TL, Monaghan MS. An evidence-based review of fat modifying supplemental weight loss products. J Obes. 2011 ; 2011: 7
26. Swislocki AL, Siegel D, Jialal I. Pharmacotherapy for the metabolic syndrome. Curr Vasc Pharmacol. 2012 ; 10 (2). 187-205
27. Hsieh YL, Yao HT, Cheng RS, Chiang MT. Chitosan reduces plasma adipocytokines and lipid accumulation in liver and adipose tissues and ameliorates insulin resistance in diabetic rats. J Med Food. 2012 ; 15 (5). 453-460
28. Liu X, Zhi X, Liu Y, Wu B, Sun Z, Shen J.. Effect of chitosan, O-carboxymethyl chitosan, and N-[(2-hydroxy-3-N,N-dimethyl-hexadecyl ammonium)propyl] chitosan chloride on overweight and insulin resistance in a murine diet-induced obesity. J Agric Food Chem. 2012 ; 60 (13). 3471-3476
29. Zhou GD, Li MR, Zhang J, et al. Chitosan ameliorates the severity of steatohepatitis induced by high fat diet in rats. Scand J Gastroenterol. 2008 ; 43 (11). 1371-1377
30. Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011 ; 14 (5). 575-585
31. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?. Curr Vasc Pharmacol. 2011 ; 9 (6). 698-705
32. Yang YY, Tsai TH, Huang YT, Lee TY, Chan CC, Lee KC, Lin HC. Hepatic endothelin-1 and endocannabinoids-dependent effects of hyperleptinemia in nonalcoholic steatohepatitis-cirrhotic rats. Hepatology. 2012 ; 55 (5). 1540-1550
33. Kshatriya S, Reams GP, Spear RM, Freeman RH, Dietz JR, Villarreal D. Obesity hypertension: the emerging role of leptin in renal and cardiovascular dyshomeostasis. Curr Opin Nephrol Hypertens. 2010 ; 19 (1). 72-78
34. Katsiki N, Yovos JG, Gotzamani-Psarrakou A, Karamitsos DT. Adipokines and vascular risk in type 2 diabetes mellitus. Angiology. 2011 ; 62 (8). 601-604
35. Athyros VG, Tziomalos K, Karagiannis A, Anagnostis P, Mikhailidis DP. Should adipokines be considered in the choice of the treatment of obesity-related health problems?. Curr Drug Targets. 2010 ; 11 (1). 122-135
36. Katsiki N, Mikhailidis DP, Gotzamani-Psarrakou A, Yovos JG, Karamitsos D. Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus. Expert Opin Ther Targets. 2011 ; 15 (4). 401-420
37. Katsiki N, Nikolic D, Montalto G, Banach M, Mikhailidis DP, Rizzo M. The role of fibrate treatment in dyslipidemia: an overview. Curr Pharm Des. 2013 ; 19 (17). 3124-3131
38. Rizzo M, Rizvi AA, Spinas GA, Rini GB, Berneis K.. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP4-inhibitors. Expert Opin Investig Drugs. 2009 ; 18 (10). 1495-1503
39. Rizzo M, Nikolic D, Banach M, et al. The effects of liraglutide on glucose, inflammatory markers, and lipoprotein metabolism: current knowledge and future perspectives. Clin Lipidol. 2013 ; 8 (2). 173-181